-
公开(公告)号：US20210371453A1
公开(公告)日：2021-12-02
申请号：US17400938
申请日：2021-08-12
申请人： Pfizer Inc.
IPC分类号： C07K1/107 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/09 , A61K47/64 , C07H3/06
摘要： The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
公开(公告)号：US10392420B2
公开(公告)日：2019-08-27
申请号：US14652723
申请日：2013-12-13
申请人： Pfizer Inc.
IPC分类号： C07K1/107 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/09 , C07H3/06 , A61K47/64 , A61K39/00
摘要： The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
3.发明授权公开(公告)号：US11872274B2
公开(公告)日：2024-01-16
申请号：US17194224
申请日：2021-03-06
申请人： Pfizer Inc.
发明人： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-Ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC分类号： A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/30
摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US20230203091A1
公开(公告)日：2023-06-29
申请号：US18176631
申请日：2023-03-01
申请人： Pfizer Inc.
IPC分类号： C07K1/107 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/09 , A61K47/64 , C07H3/06
CPC分类号： C07K1/1077 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/092 , A61K47/646 , A61K47/6415 , A61K39/09 , C07H3/06 , A61K2039/6037
摘要： The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
5.发明申请公开(公告)号：US20210196810A1
公开(公告)日：2021-07-01
申请号：US17194224
申请日：2021-03-06
申请人： Pfizer Inc.
发明人： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
6.发明申请公开(公告)号：US20200306357A1
公开(公告)日：2020-10-01
申请号：US16899738
申请日：2020-06-12
申请人： Pfizer Inc.
发明人： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
摘要： The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
7.发明授权Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 有权包含共轭荚膜糖抗原的免疫原性组合及其用途公开(公告)号：US09492559B2
公开(公告)日：2016-11-15
申请号：US14597488
申请日：2015-01-15
申请人： Pfizer Inc.
发明人： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
IPC分类号： A61K39/00 , A61K39/02 , A61K39/09 , A61K39/385 , A61K47/48
CPC分类号： A61K47/4833 , A61K39/092 , A61K47/646 , A61K2039/6037 , A61K2039/70 , Y02A50/466
摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
摘要翻译： 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。
-
公开(公告)号：US11117928B2
公开(公告)日：2021-09-14
申请号：US16923154
申请日：2020-07-08
申请人： Pfizer Inc.
IPC分类号： C07K1/107 , A61K39/095 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/09 , A61K47/64 , C07H3/06 , A61K39/00
摘要： The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
公开(公告)号：US20210121555A1
公开(公告)日：2021-04-29
申请号：US17125555
申请日：2020-12-17
申请人： Pfizer Inc.
IPC分类号： A61K39/09 , A61K39/385 , A61K39/39
摘要： The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.
-
公开(公告)号：US20200331959A1
公开(公告)日：2020-10-22
申请号：US16923154
申请日：2020-07-08
申请人： Pfizer Inc.
IPC分类号： C07K1/107 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/09 , A61K47/64 , C07H3/06
摘要： The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.021 秒)
